Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.67 |
| ▸ | RAB9A | P51151 | 2/20 | 0.67 |
| ▸ | PKM | P14618 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | MAOA | P21397 | 2/20 | 0.63 |
| ▸ | MAOB | P27338 | 2/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.56 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | CES1 | P23141 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29375440 | 1.00 | MAPT (0.67) | MAPTALDH1A1RAB9APKMTSHR | |
| Acetic Acid SCHEMBL343375 | 0.89 | MAPT (0.63) | MAPTALDH1A1RAB9APKMTSHR | |
| Allylamine SCHEMBL10375576 | 0.85 | ALDH1A1 (0.52) | MAPTALDH1A1RAB9APKMTSHR | |
| SCHEMBL11660603 | 0.84 | MAOB (0.55) | MAPTALDH1A1RAB9APKMTSHR | |
| SCHEMBL7246016 | 0.83 | TDP1 (0.64) | MAPTALDH1A1RAB9APKMTSHR | |
| SCHEMBL11575984 | 0.83 | MAPK14 (0.60) | MAPTALDH1A1RAB9APKMTSHR | |
| SCHEMBL10922670 | 0.83 | ALDH1A1 (0.54) | MAPTALDH1A1RAB9APKMTSHR | |
| SCHEMBL1918267 | 0.83 | MAPK14 (0.55) | MAPTALDH1A1RAB9APKMTSHR | |
| SCHEMBL13870503 | 0.83 | MAPK14 (0.59) | MAPTALDH1A1RAB9APKMTSHR | |
| SCHEMBL4220086 | 0.83 | MAPT (0.63) | MAPTALDH1A1RAB9APKMTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 208 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0069810-B1 | NOVEL DIBENZOXEPINS, THEIR PREPARATION, COMPOSITIONS CONTAINING THEM AND THE USE OF DIBENZOXEPINS IN THE TREATMENT OF ALLERGIC CONDITIONS | MERCK & CO. INC. (US) | 1986-12-03 | — | — | EP | claimed |
| US-4576960-A | 6,11-Dihydro-11-oxo-dibenz[b,e]oxepin derivatives | HOECHST ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1986-03-18 | — | — | US | claimed |
| EP-0069810-A1 | Novel dibenzoxepins, their preparation, compositions containing them and the use of dibenzoxepins in the treatment of allergic conditions | MERCK & CO. INC. (US) | 1983-01-19 | — | — | EP | claimed |
| JP-57140780-A | — | — | None | — | — | JP | disclosed |
| US-20250268858-A1 | Methods Of Using Low-Dose Doxepin For The Improvement Of Sleep | CURRAX PHARMACEUTICALS LLC (US) | 2025-08-28 | — | — | US | disclosed |
| WO-2024205377-A1 | NOVEL COMPOUNDS WITH MTORC2-INHIBITORY ACTIVITY AND USES THEREOF | 알리아드바이오파마 주식회사 | 2024-10-03 | — | — | WO | disclosed |
| US-12083090-B2 | Methods of using low-dose doxepin for the improvement of sleep | CURRAX PHARMACEUTICALS LLC (US) | 2024-09-10 | — | — | US | disclosed |
| US-11234954-B2 | Low-dose doxepin for treatment of sleep disorders in elderly patients | CURRAX PHARMACEUTICALS LLC (US) | 2022-02-01 | — | — | US | disclosed |
| US-20210283094-A1 | COMBINATION THERAPY USING LOW-DOSE DOXEPIN FOR THE IMPROVEMENT OF SLEEP | CURRAX PHARMACEUTICALS LLC (US) | 2021-09-16 | — | — | US | disclosed |
| US-11013712-B2 | Methods of treating insomnia using a combination therapy of low-dose doxepin and zolpidem | CURRAX PHARMACEUTICALS LLC (US) | 2021-05-25 | — | — | US | disclosed |
| US-11007168-B2 | Doxepin trans isomers and isomeric mixtures and methods of using the same to treat sleep disorders | CURRAX PHARMACEUTICALS LLC (US) | 2021-05-18 | — | — | US | disclosed |
| US-4515946-A | 6,11-Dihydro-11-oxo-dibenz-[b,e]oxepin derivatives | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1985-05-07 | — | — | US | disclosed |
| EP-0119540-A2 | Substituted alkylamine derivatives of 6,11-dihydro-11-oxodibenz (b,e)-oxepins, a process for the preparation and intermediates thereof and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1984-09-26 | — | — | EP | disclosed |
| EP-0119540-A2 | Substituted alkylamine derivatives of 6,11-dihydro-11-oxodibenz (b,e)-oxepins, a process for the preparation and intermediates thereof and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1984-09-26 | — | — | EP | disclosed |
| EP-0107134-A1 | Tricyclic antidepressant drug immunogens, antibodies, labeled conjugates, and related derivatives | MILES LABORATORIES, INC. (US) | 1984-05-02 | — | — | EP | disclosed |
| EP-0082521-A1 | 6,11-Dihydro-11,-oxo-dibenz(b,e)-oxepin derivatives, methods for their preparation, pharmaceutical compositions containing the same and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1983-06-29 | — | — | EP | disclosed |
| EP-0082521-A1 | 6,11-Dihydro-11,-oxo-dibenz(b,e)-oxepin derivatives, methods for their preparation, pharmaceutical compositions containing the same and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1983-06-29 | — | — | EP | disclosed |
| EP-0069810-A1 | Novel dibenzoxepins, their preparation, compositions containing them and the use of dibenzoxepins in the treatment of allergic conditions | MERCK & CO. INC. (US) | 1983-01-19 | — | — | EP | disclosed |
| JP-S57140780-A | PREPARATION OF DIBENZOXEPINE DERIVATIVE | DAI ICHI SEIYAKU CO LTD | 1982-08-31 | — | — | JP | disclosed |
| US-4282365-A | Dibenz[b,e]oxepin compounds | MERCK & CO., INC. (US) | 1981-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11234954-B2 | Low-dose doxepin for treatment of sleep disorders in elderly patients | UBQLN1, UBQLN2, USP47 | MAPT 819/4885ALDH1A1 2947/4885RAB9A 1644/4885 |
| US-12083090-B2 | Methods of using low-dose doxepin for the improvement of sleep | PER2, BCHE, MTNR1A | MAPT 3710/4885ALDH1A1 3713/4885RAB9A 3057/4885 |
| US-11007168-B2 | Doxepin trans isomers and isomeric mixtures and methods of using the same to treat sleep disorders | CYP3A5, CYP2D6, CYP21A2 | MAPT 1459/4885ALDH1A1 1779/4885RAB9A 2154/4885 |
| US-20250268858-A1 | Methods Of Using Low-Dose Doxepin For The Improvement Of Sleep | PER2, BCHE, MTNR1A | MAPT 3710/4885ALDH1A1 3713/4885RAB9A 3057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.